Development of STEAP-based Vaccines for the Treatment of Prostate Cancer
Abstract
Immunotherapy may provide an alternative treatment for cancer patients, especially when tumors over-expantigens that can be recognized by immune cells. The identification of markers and therapeutic targets that are up regulated in prostate cancer been important to design new potential treatments for prostate cancer. Among them, the recently identified six-transmembrane epithelial antigethe prostate (STEAP) is considered an attractive target, due to its over-expression in human prostate cancer tissues. Previously we selectprime/boost vaccination strategy (DNA/GFP-VRP) as the best scheme to induce a specific CD8 T cell response in C57BL/6 mice responsible tumor delay in complete absence of autoimmunity development but therapeutic vaccination with mSTEAP modestly controlled the growth of westablished tumors. In this report we demonstrated that CD4 T cells that produced IFNy, TNFalpha and IL-2 play the main role in tumor delay in model as demonstrated by using CD4-and CD8-deficient mice. Prime/boost vaccination was unable to control tumor progression in TRAMP with prostatic intraepithelial neoplasia, In a combined treatment of androgen ablation and STEAP vaccination was successful in prostate tubearing TRAMP mice.
Document Details
- Document Type
- Technical Report
- Publication Date
- Nov 01, 2006
- Accession Number
- ADA463511
Entities
People
- Maria De La L. Garcia-hernandez
Organizations
- University of Southern California